{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-191487","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.585305+00:00","generated_at":"2026-05-15T02:00:35.846586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Viking Therapeutics Reports Q1 2026 Net Loss of $158.3M, Cash of $603M; Phase 3 Obesity Trials Fully Enrolled","bullets":["Phase 3 VANQUISH-1 and VANQUISH-2 trials of subcutaneous VK2735 for obesity are fully enrolled; Phase 2 VENTURE study showed up to 14.7% weight loss at 13 weeks.","Initiation of Phase 3 trial for oral VK2735 expected in 4Q26; Phase 2 VENTURE-Oral showed up to 12.2% weight loss after 13 weeks.","Maintenance dosing study for VK2735 is ongoing with data expected in 3Q26; the study explores weekly, every-other-week, and monthly dosing.","IND filed for novel amylin agonist VK3019; Phase 1 trial initiation planned for 2Q26.","First quarter 2026 cash position was $603 million, with R&D expenses of $150.2 million and net loss of $158.3 million, compared to $45.6 million net loss in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-191487","json":"https://secwatch.observer/filing/0001193125-26-191487.json","markdown":"https://secwatch.observer/filing/0001193125-26-191487.md","text":"https://secwatch.observer/filing/0001193125-26-191487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/0001193125-26-191487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T02:00:35.846586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e3f086251661791dbf93734bc5180bae8c57ab5b","claim":"Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On April 29, 2026, we issued a press release reporting our financial results for the first quarter ended March 31, 2026 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/0001193125-26-191487-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}